

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 209/48, A61K 31/40	A1	(11) International Publication Number: WO 99/07679 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/GB98/00272 (22) International Filing Date: 29 January 1998 (29.01.98) (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/908,990 (CIP) Filed on 8 August 1997 (08.08.97) (71) Applicant (for all designated States except US): CHIRO-SCIENCE LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BAXTER, Andrew, Douglas [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). MON-TANA, John, Gary [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PEPTIDYL COMPOUNDS HAVING MMP AND TNF INHIBITORY ACTIVITY		
<div style="text-align: center;">$\text{R}^2\text{S}-\text{CHR}^{10}-\text{X}-\text{NR}^{11}-\text{CHR}^1-\text{Y}-\text{NR}^4\text{R}^3 \quad (I)$</div>		
(57) Abstract <p>Peptidyl compounds of general formula (I) wherein X is C=O or C=S; Y is C=O, C=S or S(O)_m where m=1-2; R¹ is C₀₋₄-alkyl-R²; R² is aryl or heteroalkyl optionally substituted have therapeutic utility via MMP and TNF inhibitory activity.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PEPTIDYL COMPOUNDS HAVING MMP AND TNF INHIBITORY ACTIVITY

Field of the Invention

This invention relates to a novel class of peptidyl derivatives, to processes for their preparation, and to their use in medicine.

5 Background of the Invention

Metalloproteinases, including matrix metalloproteinase (MMP), (human fibroblast) collagenase, gelatinase and TNF convertase (TACE), and their modes of action, and also inhibitors thereof and their clinical effects, are described in WO-A-9611209, WO-A-9712902 and WO-A-9719075, the contents of which are incorporated herein by reference.

- 10 MMP inhibitors may also be useful in the inhibition of other mammalian metalloproteinases such as the adamalysin family (or ADAMs) whose members include TNF convertase (TACE) and ADAM-10, which can cause the release of TNF α from cells, and others, which have been demonstrated to be expressed by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with multiple
- 15 sclerosis.

- Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue breakdown, such as collagenase, stromelysin and gelatinase, have been shown to inhibit the release of TNF both *in vitro* and *in vivo*. See Gearing *et al* (1994), Nature 370:555-557; McGeehan *et al* (1994), Nature 370:558-561; GB-A-2268934; and WO-A-9320047. All of these reported inhibitors contain a hydroxamic acid zinc-binding group, as do the imidazole-substituted compounds disclosed in WO-A-9523790. Other compounds that inhibit MMP and/or TNF are described in WO-A-9513289, WO-A-9611209, WO-A-96035687, WO-A-96035711, WO-A-96035712 and WO-A-96035714.
- 20

- 25 MMP inhibitors are also disclosed in WO-A-9509833 and WO-A-9519961.

Summary of the Invention

The invention encompasses novel compounds of formula (I) which are useful inhibitors of matrix metalloproteinases and/or TNF α mediated diseases including degenerative diseases (such as defined above) and certain cancers.

- 30 According to the invention, novel compounds are of general formula (I):



5 wherein:

X and Y may be C=O or C=S and may be the same or different; Y may also be S(O)_m where m=1-2;

R¹ is C₀₋₄-alkyl-R²;

R² is aryl or heteroaryl optionally substituted with R³ (heteroaryl does not include
10 unsubstituted 3-indolyl);

R³ may be C₁₋₄-alkyl, aryl, heteroaryl, halogen, OR⁶ (except when R² is aryl), N(R⁶)₂ where R⁶ may be the same or different, CO₂R⁷, COR⁶, CON(R⁶)₂ (where R⁶ may be the same or different), SO_nR⁶ (where n is 0-2 and R⁶ is not H), SO₂N(R⁶)₂ (where R⁶ may be the same or different), NR⁶COR⁶ (where R⁶ may be the same or different),
15 NR⁶CO₂R⁷ (where R⁷ is not H), NR⁶CON(R⁶)₂ (where R⁶ may be the same or different) or NR⁶SO₂R⁶ (where R⁶ may be the same or different). R³ may also be a C₁₋₄-alkyl group substituted by any group previously defined in R³;

R⁴ and R⁵ may be the same or different taken from H or C₁₋₄ alkyl;

R⁶ is H, C₁₋₄-alkyl, aryl, C₁₋₄-alkyl-aryl, heteroaryl or C₁₋₄-alkyl-heteroaryl;

20 R⁷ is H, C₁₋₄-alkyl, C₁₋₄-alkyl-aryl, or C₁₋₄-alkyl-heteroaryl;

R⁸ is H or the group COR⁹;


R⁹ is C₁₋₄ alkyl, aryl, heteroaryl, C₁₋₄ alkyl-aryl or C₁₋₄ alkyl-heteroaryl;

R¹⁰ and R¹¹ may be the same or different taken from the groups, H, C₁₋₆ alkyl, (optionally substituted with R¹²), aryl (optionally substituted with R¹²), C₁₋₆ alkyl-aryl (optionally substituted with R¹²), heteroaryl (optionally substituted with R¹²), C₁₋₆ alkyl-heteroaryl (optionally substituted with R¹²), cyclo(C₃₋₆) alkyl (optionally substituted with R¹²), C₁₋₆ alkyl-cyclo(C₃₋₆)alkyl (optionally substituted with R¹²), heterocyclo(C₄₋₆)alkyl (optionally substituted with R¹²) or C₁₋₄ alkyl-heterocyclo(C₄₋₆)alkyl (optionally substituted with R¹²);
25

30 R¹² is COR¹³, NR⁶R¹⁴, the group AR⁹ where A is O, NR⁹ or S(O)_n where n = 0-2, if A=NR⁹ the groups R⁹ may be the same or different, phthalimido or the groups:

5

10



p and q may be 0 or 1 and may be the same or different;

R and S may be CH or N and may be the same or different;

15

W may be O, S(O)_n where n = 0-2 or NR¹⁵;

Z may be H or C₀₋₄ alkyl-R¹⁸ and may be attached to any available position on the ring;

R¹³ is OR⁷, N(R⁶)₂ where R⁶ may be the same or different, C₁₋₄ alkyl, aryl, C₁₋₄ alkyl-aryl, heteroaryl or C₁₋₄ alkyl-heteroaryl;

20


R¹⁴ may be COR⁶, CO₂R⁷ (where R⁷ is not H), CON(R⁶)₂ where R⁶ may be the same or different, SO₂R¹⁶, or COR¹⁶;

R¹⁵ is H, C₁₋₄ alkyl, COR⁹, CO₂R¹⁹, CON(R⁶)₂ where R⁶ may be the same or different or SO₂R⁹;

R¹⁶ is C₁₋₄ alkyl (optionally substituted with R¹⁷);

25

R¹⁷ may be CO₂R⁶, CON(R⁶)₂ where R⁶ may be the same or different, N(R⁶)₂ where R⁶ may be the same or different, SO₂R⁹ or the groups:



R^{18} is CO_2R^6 , $\text{CON}(R^6)_2$ where R^6 may be the same or different, $\text{N}(R^6)_2$ where R^6 may be the same or different, NHCO_2R^{19} , NHSO_2R^9 or NHCOR^9 ;

R^{19} is C_{1-4} alkyl, C_{1-4} alkyl-aryl or C_{1-4} alkyl-heteroaryl;

15 and the salts, solvates, hydrates and protected amino or protected carboxy derivatives thereof.

Combinations of substituents and/or variables are only permissible if such combinations result in stable compounds.

Description of the Invention

20 Preferred compounds of the invention comprises those in which one or more of the following apply:

X is $\text{C}=\text{O}$;

Y is $\text{C}=\text{O}$ or SO_2 ;

R^{10} and R^{11} are the same or different and are selected from H and optionally-substituted alkyl, alkyl-aryl, alkyl-heteroaryl, alkyl-cycloalkyl or alkyl-heterocycloalkyl;
25 and

R^{12} is NR^6R^{14} , phthalimido or any of the said groups.

Particularly preferred compounds are given in the Examples.

It will be appreciated that the compounds according to the invention can contain
30 one or more asymmetrically substituted carbon atoms, for example those marked with an asterisk in formula (I). The presence of one or more of these asymmetric centres in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is

to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic mixtures thereof.

In the formulae herein, the ~ line is used at a potential asymmetric centre to represent the possibility of *R*- and *S*- configurations, the < line and the line to
5 represent a unique configuration at an asymmetric centre.

As used in this specification, alone or in combination, the term " C_{1-6} alkyl" refers to a straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, pentyl, hexyl and the like.

The term " C_{1-4} alkyl" refers to a straight or branched chain alkyl moiety having
10 from one to four carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl and the like.

The term " C_{0-4} alkyl" refers to a straight or branched chain alkyl moiety having from one to four carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl and the like. This term also refers to a case where a substituent, R^2 is
15 directly bonded such as in C_{0-4} -alkyl- R^2 and the like;

The term "cyclo (C_{3-6}) alkyl" refers to a saturated alicyclic moiety having from three to six carbon atoms and includes for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

The term "heterocyclo (C_{4-6}) alkyl" refers to a saturated heterocyclic moiety having
20 from three to six carbon atoms and one or more heteroatom from the group N, O, S and includes for example azetidiny, pyrrolidiny, tetrahydrofuranyl, piperidiny and the like.

There term "aryl" means an optionally substituted phenyl or naphthyl group with the substituent(s) being selected, for example, from halogen, trifluoromethyl, C_{1-6} alkyl, alkoxy, phenyl and the like.

25 The term "heteroaryl" refers to aromatic ring systems of five to ten atoms or which at least one atom is selected from the group, O, N, or S and includes for example furanyl, thiophenyl, pyridyl, indolyl, quinolyl and the like.

The term "halogen" means fluorine, chlorine, bromine or iodine.

The terms "protected amino" and "protected carboxy" mean amino and carboxy
30 groups which are protected in a manner familiar to those skilled in the art. For example, an amino group can be protected by a benzyloxycarbonyl, *tert*-butoxycarbonyl, acetyl or like groups, or in the form of a phthalimido or like group.

A carboxyl group can be protected in the form of a readily cleavable ester such as the methyl, ethyl, benzyl or *tert*-butyl ester.

Salts of compounds of formula (I) include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, such as
5 hydrochlorides, hydrobromides, p-toluenesulphonates, phosphates, sulphates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts may also be formed with bases. Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as magnesium or calcium
10 salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

When the "protected carboxy" group in compounds of the invention is an esterified carboxyl group, it may be a metabolically labile ester of formula CO_2R^{20} where R^{20} may be an ethyl, benzyl, phenethyl, phenylpropyl, α - or β -naphthyl, 2,4-
15 dimethylphenyl, 4-*tert*-butylphenyl, 2,2,2-trifluoroethyl, 1-(benzyloxy)benzyl, 1-(benzyloxy)ethyl, 2-methyl-1-propionyloxypentyl, 2,4,6-trimethylbenzyloxymethyl or pivaloyloxymethyl group.

Compounds of the general formula (I) may be prepared by any suitable method known in the art and/or by the following processes, which itself forms part of the
20 invention.

The present invention also provides a process for preparing a compound of general formula (I) as defined above. It will be appreciated that where a particular stereoisomer of formula (I) is required, the synthetic processes described herein may be used with the appropriate homochiral starting material and/or isomers may be
25 resolved from mixtures using conventional separation techniques (eg. HPLC).

The compounds according to the invention may be prepared by the following process. In the description and formulae below the groups R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R, S, W, X, Y and Z are as defined above, except where otherwise indicated. It will be appreciated that functional
30 groups, such as amino, hydroxyl or carboxyl groups, present in the various compounds described below, and which it is desired to retain, may need to be in protected form

before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction. Suitable protecting groups for such functionality will be apparent to those skilled in the art. For specific details see "Protective Groups in Organic Synthesis", Wiley Interscience, T W Greene, PGM

5 Wuts.

The process required for preparing compounds of general formula (I) comprises deprotecting (for example by hydrolysis) a compound of general formula (II)



wherein R^8 represents a suitable protecting group (eg *tert*-butyl, trityl, benzoyl or acetate).

It will be appreciated that where a particular stereoisomer of formula (I) is
15 required, this may be obtained by conventional resolution techniques such as high performance liquid chromatography. Where desired, however, appropriate homochiral starting materials may be used in the coupling reaction to yield a particular stereoisomer of formula (I). This is exemplified below.

When X and Y are $C=O$, intermediates of general formula (II) may be prepared
20 by coupling an acid of formula (III)



25 wherein R^1 , R^8 , R^{10} and R^{11} are as defined above, or an active derivative thereof, with an amine of the formula HNR^4R^5 (IV) wherein R^4 and R^5 are defined previously.

Amines of formula (IV) may be commercially available or can be readily obtained from commercially available starting materials using methods known to those skilled in the art. Active derivatives of acids of formula (III) include for example acid
30 anhydrides or acid halides, such as acid chlorides.

The coupling reaction may be performed using standard conditions for amination reactions of this type. Thus, the reaction may be achieved in a solvent, for example

an inert organic solvent such as an ether, eg. a cyclic ether such as tetrahydrofuran, an amide eg. a substituted amide such as dimethylformamide, or a halogenated hydrocarbon such as dichloromethane at a low temperature eg. -30°C to ambient temperature, such as -20°C to 0°C, optionally in the presence of as base, eg. an organic
 5 base such as an amine, eg. triethylamine or a cyclic amine such as *N*-methylmorpholine. Where an acid of formula (III) is used, the reaction may additionally be performed in the presence of a condensing agent, for example a diimide such as *N,N'*-dicyclohexylcarbodiimide, advantageously in the presence of a triazole such as 1-hydroxybenzotriazole. Alternatively, the acid may be reacted with a
 10 chloroformate for example ethylchloroformate, prior to reaction with the amine of formula (IV).

Similarly, compounds of general formula (II) may be prepared by the coupling of an acid of formula (V)



or activated derivative thereof, with an amine of formula (VI)



The amine of formula (VI) may be prepared by the coupling of a suitably
 25 protected amino-acid of formula (VII)



30 with an amine of formula (IV), followed by the removal of any protecting groups. Suitable protecting groups include carbamates such as benzyloxycarbonyl (Cbz) or *tert*-butyloxycarbonyl (Boc).

Active derivatives of acids (V) include for example acid anhydrides or acid halides such as acid chlorides as outlined earlier.

The acid of general formula (III) may be prepared by coupling an acid of formula (V), or an active derivative thereof, with an suitably protected amine of
5 formula (VII) followed by removal of any protecting groups as described previously.

α -Thioacetic acids and amino acids and their derivatives such as depicted by general formulae (V) and (VII) respectively can be obtained in optically pure or racemic form. In the homochiral form they provide asymmetric building blocks for the enantiospecific synthesis of compounds of general formula (I). Many of these
10 derivatives can be readily obtained from commercially available starting materials using methods known to those skilled in the art. See "The Practice of Peptide Synthesis" by M. Bodanszky et al, Springer Verlag, New York, (1984) and WO-A-9221360.

Compounds of general formula (II) or (V) may be prepared by nucleophilic substitution of compounds of general formula (VIII) or (IX)

15



20



respectively, wherein R^{21} represents a suitable leaving group (eg. a halogen such as bromide, or an alkylsulphonate ester such as methanesulphonate) with a thiol of general
25 formula (X)



wherein R^8 represents a suitable protecting group (eg. *tert* butyl, trityl, benzoyl or acetate),
30 using standard conditions known to those skilled in the art, as exemplified in WO-A-9005719.

Thiols of general formula (X) may be obtained from commercially available starting materials using methods known to those skilled in the art. Many thiols of general formula (X) are also commercially available.


Compounds of general formula (VIII) may be prepared by coupling an acid of
5 general formula (XI)



10 wherein R^1 , R^{21} , R^{10} and R^{11} are as defined above (or suitably protected versions thereof) or an active derivative thereof, with an amine of formula (IV) using similar coupling conditions to those described for the preparation of compounds of formula (II).

Carboxylic acids of the structure depicted in formulae (IX) and (XI) can be
15 obtained in chiral or racemic form. Many of these derivatives can be readily obtained from commercially available starting materials using methods known to those skilled in the art WO-A-9005719.

Where R^{11} is not H and amino acids of general formula (VII) are required, these may be prepared by the nucleophilic displacement of an alkylating agent of formula
20 (XIII) with an amine of formula (XIV)



wherein R^{11} and R^{21} have been defined previously.

Intermediates of formula (XIII) may be prepared from amino acids of general
30 formula (VII) by diazotisation under appropriate conditions.

Amines of formula (XIV) may be commercially available or can be readily obtained from commercially available starting materials using methods known to those skilled in the art.

Compounds of formula (I) may also be prepared by interconversion of other compounds of formula (I). Thus, for example, a compound of formula (I) wherein R^1 is a C_{1-4} alkyl- R^2 may be prepared by hydrogenation (using palladium on carbon in suitable solvent, such as an alcohol, e.g. ethanol) of a compound of formula (I) wherein R^1 is a C_{2-4} alkenyl group. As a further example, a compound of formula (I) wherein R^8 is a group R^9 CO may be prepared by acylation (using a suitable acid chloride R^9 COCl, in the presence of a base such as a triethylamine in a suitable solvent, such as a chlorinated solvent, e.g. dichloromethane) of a compound of formula (I) wherein R^8 is H.

Compounds where X and Y are C=S may be prepared by thioamidation, for instance with Lawesson's Reagent, of compounds where X and Y are C=O.

Any mixtures of final products or intermediates obtained can be separated on the basis of the physico-chemical differences of the constituents, in known manner, into the pure final products or intermediates, for example by chromatography, distillation, fractional crystallization, or by formation of a salt if appropriate or possible under the circumstances.

The compounds according to the invention exhibit *in vitro* inhibiting activities with respect to stromelysin, collagenase and gelatinase. Compounds according to the invention also exhibit *in vitro* inhibition of TNF release. The activity and selectivity of the compounds may be determined by use of the appropriate enzyme inhibition test, for example as described in Examples A-M hereinafter.

This invention also relates to a method of treatment for patients (including man and/or mammalian animals raised in the dairy, meat or fur industries or as pets) suffering from disorders or diseases which can be attributed to stromelysin as previously described, and more specifically, a method of treatment involving the administration of the matrix metalloproteinase inhibitors of formula (I) as the active constituents.

Accordingly, the compounds of formula (I) can be used among other things in the treatment of osteoarthritis and rheumatoid arthritis, and in diseases and indications resulting from the over-expression of these matrix metalloproteinases such as found in certain metastatic tumour cell lines.

As mentioned above, compounds of formula (I) are useful in human or veterinary medicine since they are active as inhibitors of TNF and MMPs. Accordingly in another aspect, this invention concerns:

a method of management (by which is meant treatment or prophylaxis) of
5 disease or conditions mediated by TNF and/or MMPs in mammals, in particular in humans, which method comprises administering to the mammal an effective, amount of a compound of formula (I) above, or a pharmaceutically acceptable salt thereof; and
a compound of formula (I) for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or
10 conditions mediated by TNF and/or MMPs; and

the use of a compound of formula (I) in the preparation of an agent for the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs.

The disease or conditions referred to above include inflammatory diseases,
15 autoimmune diseases cancer, cardiovascular diseases, diseases involving tissue breakdown such as rheumatoid arthritis, osteoarthritis, osteoporosis, neurodegeneration, Alzheimer's disease, atherosclerosis, congestive heart failure, stroke, vasculitis, Crohn's disease, ulcerative colitis, multiple sclerosis, periodontitis, gingivitis and those involving tissue breakdown such as bone resorption, haemorrhage, coagulation, acute
20 phase response, cachexia and anorexia, acute infections, HIV infections, fever, shock states, graft versus host reactions, dermatological conditions, surgical wound healing, psoriasis, atopic dermatitis, epidermolysis bullosa, tumour growth, angiogenesis and invasion by secondary metastases, ophthalmological disease, retinopathy, corneal ulceration, reperfusion injury, migraine, meningitis, asthma, rhinitis, allergic
25 conjunctivitis, eczema, anaphylaxis, restenosis, endometriosis, endosclerosis and aspirin-independent anti-thrombosis.

For the treatment of rheumatoid arthritis, osteoarthritis, and in diseases and indications resulting from the over-expression of matrix metalloendoproteinases such as found in certain metastatic tumour cell lines or other diseases mediated by the matrix
30 metalloendoproteinases or increased TNF production, the compounds of formula (I) may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit

formulations containing non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats etc, the compounds of the invention are effective in the treatment of humans.

The pharmaceutical composition containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the US Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules where in the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-

propylmethylcellulose, sodium alginate polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain
5 aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or
10 more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for
15 example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous
20 suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified, for example sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-
25 water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate
30 and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension
5 may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's
10 solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of formula (I) may also be administered in the form of
15 suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc containing
20 the compounds of Formula (I) are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)

Dosage levels of the order of from about 0.05 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above- indicated conditions (about 2.5 mg to about 7 gms per patient per day). for example, inflammation may be
25 effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day (about 0.5 mg to about 3.5 gms per patient per day).

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral
30 administration of humans may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. The following non-limiting Examples are intended to illustrate the preparation of compounds of Formula (I), and as such are not intended to limit the invention as set forth in the claims appended thereto.

In the Examples, the following abbreviations are used:

- RT Room temperature
- 10 DCC Dicyclohexylcarbodiimide
- EDC 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
- TNF α Tumour necrosis factor α
- LPS Lipopolysaccharide
- ELISA Enzyme linked immunosorbent assay
- 15 Intermediate 1 (*R,S*)-[2-(Acetylsulphonyl)-5-phthalimido]pentanoic acid
- Intermediate 2 (*S*)-[2-(Acetylsulphonyl)-5-phthalimido]pentanoic acid
- Intermediate 3 (*R*)-[2-(Acetylsulphonyl)-5-phthalimido]pentanoic acid

These three Intermediates were prepared according to the procedure described in WO-A-9611209.

- 20 Intermediate 4 (*S*)-[(1,1-Dimethylethoxy)carbonyl]-2-naphthylalanine

This Intermediate was prepared by the procedure in WO-A-9611209 for (*S*)-[(1,1-dimethylethoxy)carbonyl]-4-thiazolylalanine. A general method is as follows:

- Diethylacetamidomalonate was added to a stirred solution of sodium methoxide in methanol at room temperature. A yellow solution resulted, which was heated to 42°C
- 25 and treated in several portions with 2-bromomethyl naphthalene over the course of 2 h. The opaque solution gradually became translucent, and the internal temperature increased to 68°C. Water was then added and the resulting yellow solution allowed to cool overnight. The mixture was then re-heated to 65°C and 46-48% sodium hydroxide solution was then added over a 2 h. The mixture was then allowed to cool overnight.
- 30 The mixture was adjusted to pH 9 with 6M HCl and the solution stirred at 26°C. Following a dichloromethane work-up, the N-acetyl acid was subjected to

biotransformation using amino acylase at pH 8, followed by Boc protection using Boc anhydride (1.1 equiv) in methanol at 0°C. The product was isolated as a white solid.

Intermediate 5 **(S)-[(1,1-Dimethylethoxy)carbonyl]-2-naphthylalanine N-methylamide**

- 5 A solution of Intermediate 4 (12.06 g) in tetrahydrofuran (121 ml, 10 vols) at 0°C under a nitrogen blanket was treated with DCC (1.1 equiv., 8.67 g) and *N*-hydroxysuccinimide (1.1 equiv., 4.84 g). A white precipitate formed. After 3 h stirring at 0°C the precipitate was filtered and the residue washed with the minimum volume of tetrahydrofuran. The filtrate was then cooled to 0°C and treated dropwise with aqueous
- 10 methylamine (40% aqueous solution, 3.0 equiv., 9.61 ml). The precipitate was filtered and the residue washed with tetrahydrofuran. The filtrate was evaporated *in vacuo* to give the product as a white solid which was used directly in the next step.

TLC R_f 0.75 (EtOAc).

Intermediate 6 **2-Naphthylalanine N-methylamide**

- 15 A solution of Intermediate 5 (12.46 g) in dichloromethane (124 ml) at 0°C was treated dropwise with neat trifluoroacetic acid (120 ml). The resulting pale yellow solution was allowed to reach room temperature over 48 h. The solvent was subsequently removed and the crude product dissolved in the minimum volume of 1N hydrochloric acid at 0°C. The aqueous phase was extracted with dichloromethane to
- 20 remove any impurities. The aqueous phase was then taken to pH 8.5, initially using solid sodium bicarbonate and then a few drops of 3N sodium hydroxide. A white precipitate formed which was filtered, and the residue washed with water and dried *in vacuo* (7.2 g 83%).

TLC R_f 0.10 (EtOAc).

- 25 **Example 1** **(S)-[2-(Acetylsulphonyl)-5-phthalimido]pentanoyl-(S)-2-naphthylalanine N-methylamide**

- A solution of Intermediate 5 (0.29 g) in dichloromethane (5.8 ml) at 0°C was treated with Intermediate 2 (0.41 g). EDC (0.267 g) and *N*-hydroxybenzotriazole (0.18 g) were then added and the resulting pale yellow solution was stirred under a nitrogen
- 30 blanket overnight. 1N hydrochloric acid (2 mL) was added and the mixture shaken thoroughly; *N*-hydroxybenzotriazole precipitated from the acid phase and was removed

by filtration. The organic phase was evaporated *in vacuo* to give the title compound as a white solid (75%).

TLC R_f 0.7 (EtOAc).

Similarly prepared were:

- 5 **Example 2** (R)-[2-(Acetylsulphonyl)-5-phthalimido]pentanoyl-(S)-2-naphthylalanine N-methylamide

From Intermediate 3 and Intermediate 5, as a white solid (80%).

TLC R_f 0.72 (EtOAc).

- 10 **Example 3** (R, S)-[2-(Acetylsulphonyl)-5-phthalimido]pentanoyl-(S)-2-naphthylalanine N-methylamide

From Intermediate 1 and Intermediate 5, as a white solid (77%).

TLC R_f 0.68 (EtOAc).

- Example 4** (R)-[2-(Sulphonyl)-5-phthalimido]pentanoyl-(S)-2-naphthylalanine N-methylamide

- 15 A solution of Example 3 (0.80 g) in methanol (16 ml) at 0°C was treated with aqueous ammonia (3.2 ml) under a nitrogen blanket. The clear, colourless solution was stirred at 0°C for 2 h. The solution was directly preadsorbed onto silica and purified using flash column chromatography on a de-gassed column, eluting with 3% methanol in dichloromethane to liberate the title compound as a white solid (0.3 g, 41%).

- 20 TLC R_f 0.4 (EtOAc)

Similarly prepared were:

- Example 5** (S)-[2-(Sulphonyl)-5-phthalimido]pentanoyl-(S)-2-naphthylalanine N-methylamide

From Example 1, as a white solid (52%).

- 25 TLC R_f 0.38 (EtOAc)

- Example 6** (R,S)-[2-(Sulphonyl)-5-phthalimido]pentanoyl-(S)-2-naphthylalanine N-methylamide

From Example 3, as a white solid (48%).

TLC R_f 0.42 (EtOAc)

Example A**Collagenase inhibition activity**

The potency of compounds of general formula (I) to act as inhibitors of collagenase was determined by the procedure of Cawston and Barrett, (Anal. Biochem., 5 99:340-345, 1979) whereby a 1mM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with collagen and collagenase (buffered with 50 mM Tris, pH 7.6 containing 5 mM CaCl₂, 0.05% Brij 35, 60 mM NaCl and 0.02% NaN₃). The collagen was acetylated ³H or ¹⁴C-collagen prepared by the method of Cawston and Murphy (Methods in Enzymology, 80:711, 1981). The choice of radiolabel 10 did not alter the ability of collagenase to degrade the collagen substrate. The samples were centrifuged to sediment undigested collagen and an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of 1mM inhibitor, or a dilution thereof, was compared to activity in a control devoid of inhibitor and the results reported as that inhibitor concentration 15 effecting 50% inhibition of the collagenase (IC₅₀).

Example B**Stromelysin inhibition activity**

The potency of compounds of general formula (I) to act as inhibitors of stromelysin was determined using the procedure of Nagase et al (Methods in Enzymology Vol 254, 20 1994), whereby a 0.1 mM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with stromelysin and ³H transferrin (buffered with 50 mM Tris, pH 7.6 containing 10 mM CaCl₂, 150M NaCl, 0.05% Brij, 35, and 0.02% NaN₃). The transferrin was carboxymethylated with ³H iodoacetic acid. The stromelysin activity in the presence of 1 mM, or a dilution thereof, was compared to activity in a control 25 devoid of inhibitor and the results reported as that inhibitor concentration effecting 50% inhibition of the stromelysin (IC₅₀)

Example C**Gelatinase inhibition activity**

The potency of the compounds of general formula (I) to act as inhibitors of 30 gelatinase was determined using the procedure of Harris & Krane (Biochem Biophys. Acta, 258:566 - 576, 1972), whereby a 1 mM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with gelatinase and heat denatured

^3H or ^{14}C -acetylated collagen (buffered with 50 mM Tris, pH 7.6 containing 5 mM CaCl_2 , 0.05% Brij 35 and 0.02% NaN_3). The ^3H or ^{14}C gelatin was prepared by denaturing ^3H or ^{14}C -collagen produced according to the method of Cawston and Murphy (Methods in Enzymology, 80:711, 1981) by incubation at 60°C for 30 minutes. Undigested gelatin was
5 precipitated by addition of trichloroacetic acid and centrifugation. The gelatinase activity in the presence of 1 mM, or dilution thereof, was compared to the activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the gelatinase (IC_{50}).

Example D

10 MMP Inhibition Activity-Fluorimetric Assay

The potency of compounds of general formula (I) to act as inhibitors of collagenase-1(MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), gelatinase-A (MMP-2), gelatinase-B (MMP-9) and stromelysin-1(MMP-3) was determined using the following procedure:

15 Inhibitors are dissolved in dimethylsulphoxide containing 0.02% β -mercaptoethanol and serial dilutions are prepared. Activated enzyme is incubated in assay buffer containing 50mM Tris, pH 7.4, 5mM CaCl_2 , 0.002% NaN_3 and Brij 35 in the presence and absence of inhibitor. Samples are preincubated at 37°C for 15 minutes before the addition of the fluorimetric substrate (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg- NH_2) to a final concentration
20 of 10 μM . The assay is incubated for 20-30 min at 37°C and then read in a Fluoroscan II at λ_{ex} (340nm) and λ_{em} (405nm).

The enzyme activity was compared to activity in a control devoid of inhibitor and the results reported as that inhibitor concentration effecting 50% inhibition of the stromelysin (IC_{50}).

25 Example E

Inhibition of $\text{TNF } \alpha$ production

The potency of the compounds of general formula (I) to act as inhibitors of the production of $\text{TNF } \alpha$ is determined using the following procedure. A 100 μM solution of the inhibitor being tested or dilutions thereof is incubated at 37° C in an atmosphere of 5%
30 CO_2 with THP-1 cells (human monocytes) suspended in RPMI 1640 medium and 20 μM β -mercaptoethanol at a cell density of $1 \times 10^6/\text{ml}$ and stimulated with LPS. After 18 hours

the supernatant is assayed for the levels of TNF α using a commercially available ELISA kit (R & D Systems).

The activity in the presence of 0.1mM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor
5 concentration effecting 50% inhibition of the production of TNF α .

Example F

Inhibition of L-selectin shedding

Compounds of general formula (I) are evaluated in an assay of L-selectin shedding by peripheral blood mononuclear cells (PBMC). PBMC are isolated from buffy coats by
10 standard procedures using Ficoll. A 100 μ M solution of the inhibitor being tested or dilutions thereof is incubated for 20min at 37° C in an atmosphere of 5% CO₂ with 4 x 10⁶/ml PBMC stimulated with PMA. The cells are centrifuged down and the supernatants tested for sL-selectin using a commercially available ELISA kit (R & D Systems).

The activity in the presence of 100 μ M inhibitor or dilutions thereof was compared
15 to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of L-selectin.

Example G

Inhibition of sII-1RII shedding

Compounds of general formula (I) are evaluated in an assay of sII-1RII shedding
20 by peripheral blood mononuclear cells (PBMC). PBMC are isolated from buffy coats by standard procedures using Ficoll. A 100 μ M solution of the inhibitor being tested or dilutions thereof are incubated for 18h at 37° C in an atmosphere of 5% CO₂ with 2 x 10⁶/ml PBMC stimulated with II-13. The cells are centrifuged down and the supernatants tested for sII-1RII using a commercially available ELISA kit (R & D Systems).

25 The activity in the presence of 100 μ M inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of sII-1RII.

Example H

Inhibition of II-6R shedding

30 Compounds of general formula (I) are evaluated in an assay of sII-6R shedding by HL-60 cells. PBMC are isolated from buffy coats by standard procedures using Ficoll. A 100 μ M solution of the inhibitor being tested or dilutions thereof is incubated for 24h

at 37° C in an atmosphere of 5% CO₂ with 2 x 10⁶/ml HL-60 cells stimulated with PMA. The cells are centrifuged down and the supernatants tested for sIL-6R using a commercially available ELISA kit (R & D Systems).

The activity in the presence of 100μM inhibitor or dilutions thereof is compared
5 to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of IL-6R.

Example I

Inhibition of TNF RII shedding

The potency of the compounds of general formula (I) to act as inhibitors of the
10 shedding of TNF RII is determined using the following procedure. A 100μM solution of the inhibitor being tested or dilutions thereof are incubated at 37° C in an atmosphere of 5% CO₂ with THP-1 cells (human monocytes) suspended in RPMI 1640 medium and 20μM β-mercaptoethanol at a cell density of 1 x 10⁶/ml and stimulated with LPS. After 18 hours the supernatant is assayed for the levels of sTNF RII using a commercially
15 available ELISA kit (R & D Systems).

The activity in the presence of 0.1mM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of TNF RII.

Example J

20 Adjuvant arthritic rat model

Compounds of general formula (I) were evaluated in an adjuvant arthritis model in the rat based on the methods employed by B.B. Newbould (1963), Br.J.Pharmacol, 21, 127-136 and C.M. Pearson and F.D. Wood (1959), Arthritis Rheum, 2, 440-459. Briefly male Wistar rats (180-200g) were injected at the base of the tail with Freund's adjuvant.
25 Twelve days later the responding animals were randomised into experimental groups. Compounds of general formula (I) were dosed either orally as a suspension in 1% methyl cellulose or intraperitoneally in 0.2% carboxymethylcellulose from day 12 to the end of the experiment on day 22. Hind paw volumes were measured every two days from day 12 onwards and X-rays were taken of the hind feet on completion of the experiment.
30 Results were expressed as the percent increase of foot volume over day 12 values.

Example K**Mouse ovarian carcinoma xenograft model**

Compounds of general formula (I) were evaluated in an ovarian carcinoma xenograft model of cancer, based on that described by B. Davies et al (1993), Cancer Research, 53, 2087-2091. This model, in brief, consists of inoculating female nu/nu mice with 1×10^9 OVCAR3-icr cells into the peritoneal cavity. Compounds of general formula (I) are administered by the oral route as a suspension in 1% methyl cellulose or intraperitoneally as a suspension in phosphate buffered saline in 0.01% Tween-20. At the conclusion of the experiment (4-5 weeks) the number of peritoneal cells are counted and any solid tumour deposits weighed. In some experiments tumour development is monitored by measurement of tumour specific antigens.

Example L**Rat mammary carcinoma model**

Compounds of general formula (I) were evaluated in a HOSP.1 rat mammary carcinoma model of cancer (S.Eccles et al (1995), Cancer Research, in press). This model consists of the intravenous inoculation of female CBH/cbi rats with 2×10^4 tumour cells into the jugular vein. Compounds of general formula (I) are administered by the oral route as a suspension in 1% methyl cellulose or intraperitoneally as a suspension in phosphate buffered saline + 0.01% Tween-20. At the conclusion of the experiment (4-5 weeks) the animals are killed, the lungs are removed and individual tumours counted after 20 hours fixation in Methacarn.


Example M**Mouse B16 melanoma model**

The anti-metastatic potential of compounds of general formula (I) is evaluated in a B16 melanoma model in C57BL/6. Mice are injected intravenously with 2×10^5 B16/F10 murine tumour cells harvested from *in vitro* cultures. Inhibitors are administered by the oral route as a suspension in 1% methyl cellulose or intraperitoneally as a suspension in phosphate buffered saline pH7.2 + 0.01% Tween-20. Mice are killed 14 days after cell inoculation and the lungs removed and weighed prior to fixing in Bouin's solution. The number of colonies present on the surface of each set of lungs is then counted by eye.

These assay procedures may also be found in PCT/GB97/02129.

CLAIMS

1. A compound of general formula (I):



wherein X is C=O or C=S;

Y is C=O, C=S or S(O)_m where m=1-2;

R¹ is C₀₋₄-alkyl-R²;

10 R² is aryl or heteroaryl optionally substituted with R³ (provided that heteroaryl is not unsubstituted 3-indolyl);

R³ is C₁₋₄-alkyl optionally substituted by any R³ group, aryl, heteroaryl, halogen, OR⁶ (except when R² is aryl), N(R⁶)₂, CO₂R⁷, COR⁶, CON(R⁶)₂, SO₂R⁶, SO₂N(R⁶)₂, NR⁶COR⁶, NR⁶CO₂R⁷ (where R⁷ is not H), NR⁶CON(R⁶)₂, or NR⁶SO₂R⁶;

15 R⁴ and R⁵ are the same or different and are each H or C₁₋₄ alkyl;

R⁶ is H, C₁₋₄-alkyl, aryl, C₁₋₄-alkyl-aryl, heteroaryl or C₁₋₄-alkyl-heteroaryl, and each R⁶ in N(R⁶)₂ may be the same or different;

R⁷ is H, C₁₋₄-alkyl, C₁₋₄-alkyl-aryl or C₁₋₄-alkyl-heteroaryl;

R⁸ is H or the group COR⁹;


20 R⁹ is C₁₋₄ alkyl, aryl, heteroaryl, C₁₋₄ alkyl-aryl or C₁₋₄ alkyl-heteroaryl;

R¹⁰ and R¹¹ are the same or different and are selected from H or a group (optionally substituted with R¹²) selected from C₁₋₆ alkyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl, cyclo(C₃₋₆) alkyl, C₁₋₆ alkyl-cyclo(C₃₋₆)alkyl, heterocyclo(C₄₋₆)alkyl and C₁₋₄ alkyl-heterocyclo(C₄₋₆)alkyl;

25 R¹² is COR¹³, NR⁶R¹⁴, AR⁹ where A is O, NR⁹ or S(O)_n where n = 0-2 and, if A=NR⁹ the groups R⁹ may be the same or different, phthalimido or any of the groups:

5

10



p and q are 0 or 1 and are the same or different;

R and S are CH or N and are the same or different;

15

W is O, $S(O)_n$ where $n = 0-2$ or NR^{15} ;

Z is H or C_{0-4} alkyl- R^{18} and may be attached to any available position on the ring;

R^{13} is OR^7 , $N(R^6)_2$, C_{1-4} alkyl, aryl, C_{1-4} alkyl-aryl, heteroaryl or C_{1-4} alkyl-heteroaryl;


20

R^{14} is COR^6 , CO_2R^7 (where R^7 is not H), $CON(R^6)_2$, SO_2R^{16} or COR^{16} ;

R^{15} is H, C_{1-4} alkyl, COR^9 , CO_2R^{19} , $CON(R^6)_2$ or SO_2R^9 ;

R^{16} is C_{1-4} alkyl (optionally substituted with R^{17});

R^{17} is CO_2R^6 , $CON(R^6)_2$, $N(R^6)_2$, SO_2R^9 or any of the groups:



R^{18} is CO_2R^6 , $\text{CON}(R^6)_2$, $\text{N}(R^6)_2$, NHCO_2R^{19} , NHSO_2R^9 or NHCOR^9 ; and

R^{19} is C_{1-4} alkyl, C_{1-4} alkyl-aryl or C_{1-4} alkyl-heteroaryl;

15 or a salt, solvate, hydrate or protected amino or protected carboxy derivative thereof.

2. A compound of claim 1, wherein X is $\text{C}=\text{O}$.

3. A compound of claim 1 or claim 2, wherein Y is $\text{C}=\text{O}$ or SO_2 .

4. A compound of any preceding claim, wherein R^{10} and R^{11} are the same or different
20 and are selected from H and optionally-substituted alkyl, alkyl-aryl, alkyl-heteroaryl, alkyl-cycloalkyl or alkyl-heterocycloalkyl.

5. A compound of any preceding claim, wherein R^{12} is NR^6R^{14} , phthalimido or any of the said groups.

6. A compound of any preceding claim, wherein R^2 is optionally substituted naphthyl.

25 7. A compound of claim 1, which is

(S) -[2-(Acetylsulphanyl)-5-phthalimido]pentanoyl- (S) -2-naphthylalanine

N-methylamide,

(R) -[2-(Acetylsulphanyl)-5-phthalimido]pentanoyl- (S) -2-naphthylalanine

N-methylamide,

30 (R, S) -[2-(Acetylsulphanyl)-5-phthalimido]pentanoyl- (S) -2-naphthylalanine

N-methylamide,

(R) -[2-(Sulphanyl)-5-phthalimido]pentanoyl- (S) -2-naphthylalanine *N*-methylamide,

(*S*)-[2-(Sulphanyl)-5-phthalimido]pentanoyl-(*S*)-2-naphthylalanine *N*-methylester,

or

(*R,S*)-[2-(Sulphanyl)-5-phthalimido]pentanoyl-(*S*)-2-naphthylalanine

N-methylester.

- 5 8. A compound of any preceding claim, in the form of a single enantiomer or diastereomer.
9. A pharmaceutical composition for use in therapy, comprising a compound of any preceding claim, and a pharmaceutically-acceptable diluent or carrier.
10. Use of a compound of any of claims 1 to 8, for the manufacture of a
- 10 medicament for the treatment or prevention of a condition associated with matrix metalloproteinases or that is mediated by TNF α or enzymes involved in the shedding of *L*-selectin, the TNF receptors or IL-6 receptors.
11. Use according to claim 10, wherein the condition is selected from cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease,
- 15 ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft versus host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-independent anti-thrombosis.
12. Use according to claim 10, wherein the condition is selected from tumour
- 20 growth, angiogenesis, tumour invasion and spread, metastases, malignant ascites and malignant pleural effusion.
13. Use according to claim 10, wherein the condition is selected from cerebral ischaemia, ischaemic heart disease, rheumatoid arthritis, osteoarthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's, atherosclerosis, stroke,
- 25 vasculitis, Crohn's disease and ulcerative colitis.
14. Use according to claim 10, wherein the condition is selected from corneal ulceration, retinopathy and surgical wound healing.
15. Use according to claim 10, wherein the condition is selected from psoriasis, atopic dermatitis, chronic ulcers and epidermolysis bullosa.
- 30 16. Use according to claim 10, wherein the condition is selected from periodontitis and gingivitis.

17. Use according to claim 10, wherein the condition is selected from rhinitis, allergic conjunctivitis, eczema and anaphylaxis.

18. Use according to claim 10, wherein the condition is selected from restenosis, congestive heart failure, endometriosis, atherosclerosis and endosclerosis.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00272

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D209/48 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 13289 A (CHIROSCIENCE LTD.) 18 May 1995 see claims ---	1, 10
A	WO 96 11209 A (CHIROSCIENCE LTD.) 18 April 1996 see claims ---	1, 10
A	WO 95 09833 A (FLORIDA STATE UNIVERSITY) 13 April 1995 see claims ---	1, 10
A	WO 95 19961 A (BRITISCH BIOTECH PHARMACEUTICALS LTD) 27 July 1995 see claims -----	1, 10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 May 1998

Date of mailing of the international search report

12/06/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00272

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9513289 A	18-05-1995	AU 679286 B AU 8113394 A BR 9408025 A CN 1134705 A CZ 9601349 A EP 0728144 A FI 961976 A HU 73799 A JP 9505041 T NO 961888 A PL 314300 A	26-06-1997 29-05-1995 17-12-1996 30-10-1996 16-10-1996 28-08-1996 09-05-1996 30-09-1996 20-05-1997 09-05-1996 02-09-1996
WO 9611209 A	18-04-1996	AU 3612795 A CZ 9700996 A EP 0784629 A FI 971412 A HU 77282 A NO 971537 A PL 319503 A	02-05-1996 17-09-1997 23-07-1997 04-04-1997 30-03-1998 04-06-1997 18-08-1997
WO 9509833 A	13-04-1995	US 5455262 A AU 7963394 A EP 0722436 A	03-10-1995 01-05-1995 24-07-1996
WO 9519961 A	27-07-1995	AU 678884 B AU 1460395 A AU 1654097 A CA 2181709 A EP 0740655 A FI 962905 A GB 2300188 A GB 2315750 A HU 74511 A JP 9508362 T NO 963031 A	12-06-1997 08-08-1995 22-05-1997 27-07-1995 06-11-1996 19-07-1996 30-10-1996 11-02-1998 28-01-1997 26-08-1997 20-09-1996